Today

Synlogic's common stock was suspended from Nasdaq trading on January 21, 2026, after the company withdrew its appeal against delisting.

Synlogic's common stock will be suspended from Nasdaq trading on January 21, 2026, after the company withdrew its appeal against delisting.

Worthington Steel amended its Q4 fiscal 2026 earnings, reporting a larger net loss due to additional impairment charges and loan commitment costs.

River Financial Corp confirmed data removal in a cybersecurity incident and now faces two class action lawsuits, increasing legal risk.

River Financial Corp updated on its cybersecurity incident, confirming potential data impact but no account impact, with material business consequences still undetermined.

Worthington Steel reported a significant net loss for Q4 fiscal 2026 due to impairments and acquisition costs, while also announcing a new Corporate Controller and a quarterly dividend.

River Financial Corporation disclosed a ransomware attack that affected its network and operations, with the full impact still under investigation.

Newmark Group repurchased 11 million shares from its former Executive Chairman and announced a transfer of voting control to comply with ethics rules.

Hawaiian Electric reached a definitive $1.99 billion settlement for Maui wildfire tort claims, reducing significant legal and financial uncertainty.

Equinix is facing an independent investigation by its Audit Committee and a federal subpoena related to a short seller report.

AT&T disclosed a material cybersecurity incident involving the unauthorized access of customer call and text logs from a third-party cloud platform.

TeraWulf reported increased bitcoin production and hash rate for March, alongside efficiency gains and plans to expand capacity to 10 EH/s by mid-2024.

Gauzy Ltd. has completed its initial public offering, raising $75 million in gross proceeds.

Churchill Capital Corp X has completed its initial public offering, raising $414 million for its SPAC operations.

Outlook Therapeutics' appeal for its nAMD treatment, ONS-5010/LYTENAVA™, has been granted by the FDA, paving the way for a BLA resubmission.

Arvinas received FDA approval for VEPPANU, its lead PROTAC drug for advanced breast cancer, triggering a $50 million milestone payment.

Capricor Therapeutics announced an FDA Advisory Committee meeting for its Duchenne muscular dystrophy therapy, Deramiocel, ahead of an August PDUFA date.

Intellia Therapeutics increased its at-the-market offering program by $285.3 million to a total of $1.035 billion, alongside news of an FDA clinical hold lift.

Ultragenyx's gene therapy for GSDIa received FDA Priority Review, setting an August 2026 action date.

Ultragenyx received FDA clearance for its IND application for UX016, enabling a Phase 1/2 study for GNE myopathy.